Heather Martin, NP
Primary Care · Seneca, SCNPI 1083278279
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 377 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Boston Scientific at 24.1% of the total. Among primary care clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 377 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Lilly USA, LLC$678
- Bayer$565
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$532
- GSK$402
- AbbVie$392
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,873100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 72 | $1,659 |
| Lilly USA, LLC | 46 | $678 |
| Bayer | 37 | $565 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $532 |
| GSK | 24 | $402 |
| AbbVie | 23 | $392 |
| Novo Nordisk | 20 | $359 |
| Pfizer | 17 | $302 |
| Novartis | 11 | $231 |
| Amgen | 13 | $202 |
| Biosense Webster, Inc. | 1 | $144 |
| Boehringer Ingelheim | 8 | $136 |
| AstraZeneca | 8 | $135 |
| Sanofi-aventis U.S. LLC | 7 | $118 |
| Exact Sciences | 7 | $116 |
| Paratek Pharmaceuticals, Inc. | 6 | $116 |
| Esperion Therapeutics, Inc. | 7 | $100 |
| Johnson & Johnson | 6 | $92 |
| Dexcom, Inc. | 5 | $77 |
| Cardiva Medical, Inc. | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $54 |
| Nestle Healthcare Nutrition Inc. | 3 | $47 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 3 | $37 |
| Insmed, Inc. | 2 | $35 |
| Abiomed | 1 | $28 |
| Merck | 2 | $27 |
| Cardinal Health 200 LLC | 2 | $24 |
| Almatica Pharma LLC | 1 | $23 |
| Lucid Diagnostics Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Medicure Pharma Inc. | 1 | $11 |
| Vivus LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Farapulse$264
- Carto 3$144
- WATCHMAN FLX$141
- LUX-Dx Insertable Cardiac Monitor$102
How this compares
$6,873 in reported general payments places this provider in the 90th percentile of 115 primary care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $83,784 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $40,911 |
| MounjaroTirzepatide | 27 | $38,435 |
| EliquisApixaban | 26 | $36,868 |
| JardianceEmpagliflozin | 17 | $29,573 |
| XareltoRivaroxaban | 17 | $15,957 |
| Repatha SureclickEvolocumab | 17 | $13,433 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $11,650 |
| InvokanaCanagliflozin | 12 | $11,461 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $9,411 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $8,865 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $6,861 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 139 | $4,243 |
| Rosuvastatin Calcium | 288 | $2,911 |
| SingulairMontelukast Sodium | 11 | $2,748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $359 | $83,78463 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $402 | $47,77142 claims |
| Lilly USA, LLCMounjaro | $678 | $38,43527 claims |
| PfizerEliquis | $302 | $36,86826 claims |
| Boehringer IngelheimJardiance | $136 | $29,57317 claims |
| Johnson & JohnsonXarelto, Invokana | $92 | $27,41829 claims |
| AstraZenecaBreztri Aerosphere | $135 | $8,86512 claims |
| AbbVieSynthroid | $392 | $1,31929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 115 primary care providers in South Carolina.
Other primary care in Seneca
- Cynthia SmithSeneca$10K
- Henrietta OkonkworSeneca$1K
- Sarah TomashefskiGreenville$23K
- Samantha VaughtNorth Myrtle Beach$15K
- William ByrdSumter$10K
- Kathleen BoonePawleys Island$9K
- Amanda GroomeGreenville$9K
- Holly SurrencyAiken$8K
- Jessica BoldenAnderson$8K
- Caren ArnetteDillon$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.